NCT03715205View on ClinicalTrials.gov

Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 31, 2019

Primary Completion Date

August 21, 2024

Study Completion Date

August 21, 2024

Conditions
Carcinoma, Non-Small-Cell LungMelanoma
Interventions
DRUG

Pembrolizumab

Administered as an intravenous (IV) infusion every 3 weeks (Q3W)

Trial Locations (8)

110029

All India Institute of Medical Sciences ( Site 0012), New Delhi

110076

Indraprastha Apollo Hospitals ( Site 0008), New Delhi

110085

Rajiv Gandhi Cancer Institute and Research Centre ( Site 0003), Delhi

122001

Artemis Health Institute ( Site 0007), Gurgaon

400012

Tata Memorial Hospital [M] ( Site 0005), Mumbai

400053

Kokilaben Ben Dhirubhai Ambani Hosp & Med Res Inst. ( Site 0001), Mumbai

411004

Deenanath Mangeshkar Hospital and Research Center ( Site 0009), Pune

500082

Nizam's Institute of Medical Sciences ( Site 0011), Hyderabad

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03715205 - Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | Biotech Hunter | Biotech Hunter